PFNXinactive

Pfenex Inc.

Healthcare·Oncology·Commercial
OncologyMusculoskeletal

Pfenex Inc. (PFNX): 6 pipeline candidates · ~35 mo cash runway. Updated within the last hour.

9.7/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway9.7

35.0 months

Financial Health9.8

D/E 0.16 · 0% dilution

Pipeline Maturity9.5

Lead: BLA Filed

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Pfenex Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$61.2M

Quarterly Burn

$5.3M

Runway

35.0 mo

Revenue

$781K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~May 2029
Today~39 mo out
Catalyst within runway

Pipeline (6 candidates)

·CEO: California April

Frequently asked questions

How many drug candidates are in Pfenex Inc.'s pipeline?

Pfenex Inc. (PFNX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Pfenex Inc.'s lead drug candidate?

Pfenex Inc.'s most advanced tracked candidate is pf708 (BLA Filed) for osteoporosis.

What is Pfenex Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Pfenex Inc. has approximately 35.0 months of cash runway.

Who is the CEO of Pfenex Inc.?

California April is the chief executive officer of Pfenex Inc. (PFNX).

Get the full picture on Pfenex Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.